Local biotech companies Seattle Genetics and Alder BioPharmaceuticals both posted losses in their earnings reports this week, keeping with the trend of biotechs opting for investment rather than profit.
Cancer drug company Seattle Genetics (Nasdaq: SGEN) on Thursday reported higher sales of its Adcetris drug for the first quarter.
Adcetris revenue came to $58.6 million in the first quarter, which was a 20 percent increase from $48.9 million in the year-earlier period.
Those figures are only for…
Local biotech companies Seattle Genetics and Alder BioPharmaceuticals both posted losses in their earnings reports this week, keeping with the trend of biotechs opting for investment rather than profit.
Cancer drug company Seattle Genetics (Nasdaq: SGEN) on Thursday reported higher sales of its Adcetris drug for the first quarter.
Adcetris revenue came to $58.6 million in the first quarter, which was a 20 percent increase from $48.9 million in the year-earlier period.
Those figures are only for…